PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Sagefrog Marketing Group, LLC

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

ImpactRx Launches New Pulmonologist Research Panel - Company expands nationwide longitudinal network of high-value iPhone-connected physicians to include Pulmonologists - ImpactRx.com
ImpactRx Launches New Pulmonologist Research Panel

 

NewswireToday - /newswire/ - Mount Laureal, NJ, United States, 2011/03/31 - Company expands nationwide longitudinal network of high-value iPhone-connected physicians to include Pulmonologists - ImpactRx.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

ImpactRx, the pioneer in measuring the impact of promotion on physician prescribing behavior announced today that it is expanding its nationwide network of longitudinal panels of iPhone-connected physicians with the addition of the pulmonologist specialty.

“The respiratory market has been re-energized and will become increasingly competitive with the introduction of new treatment alternatives,” stated Richard Altus, President and Chief Executive Officer of ImpactRx. “For example, Merck recently launched DuleraTM for asthma. In addition, the COPD market which already includes high-powered competitors such as Pfizer’s and Boehringer-Ingelheim’s SpirivaTM, GSK’s AdvairTM and AstraZeneca’s SymbicortTM, will become even more active with the entry of Forest’s recently approved Daliresp™”, commented Altus.

“Competitors in this marketplace will need to work harder for a share of the pulmonologist’s attention,” said Altus,“and ImpactRx’s unique point-of-promotion and point-of-treatment research model will provide our clients unmatched insight into the impact of their promotional efforts.”

ImpactRx’s proprietary data capture methodology, integrated with its high-level analytics and full custom research capabilities, provides its clients unique visibility into the effectiveness of their launch and post-launch market strategies. Through its ImpactData™, the Company continuously captures feedback from high-value physicians in real-time to provide data that gives clients a closer view of the relationship between physician prescribing and such influencing metrics as promotional activity, sales representative quality and marketplace dynamics.
The addition of pulmonologists to the twelve already existing physician specialty panels in the ImpactRx network - including Primary Care, Oncology, Endocrinology, and Neurology - expands and strengthens the comprehensive brand and marketing research solutions offered by ImpactRx.

About ImpactRx

Founded in 2000 and headquartered in Mount Laurel, N.J., ImpactRx’s longitudinal panels of high value, iPhone-connected physicians is the exclusive source of continuously captured promotion and treatment data. Through its proprietary methodology, the Company annually captures one million details and three-million treatment decisions, fueling its unique ImpactData™ industry database. ImpactRx (impactrx.com) leverages this unprecedented intelligence with custom research and analytics to provide insightful solutions to pharmaceutical marketing and sales decision makers.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Sagefrog Marketing Group, LLC

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


ImpactRx Launches New Pulmonologist Research Panel

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Leslie Bailey - ImpactRx.com 
856-802-4133 lbailey[.]impactrx.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Sagefrog Marketing Group, LLC securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Sagefrog Marketing Group, LLC / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Ipsen Announces Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival
First Patient Treated with Microscopic Beads Pre-loaded with A Targeted Cancer Drug and Visible on CT Scans
BTG Plc Acquires Roxwood Medical
BTG and Mirada Medical Sign Three-Year Software Development Agreement
U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  RightITnow Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)